期刊
MEDICINA CLINICA
卷 160, 期 1, 页码 23-26出版社
ELSEVIER ESPANA SLU
DOI: 10.1016/j.medcli.2022.04.017
关键词
Bronchiectasis; Hypertonic saline; Sputum expectoration; Bronchial hypersecretion; Mucoactive treatment
Nebulized hypertonic saline improves the quality of life and reduces exacerbations in patients with cystic fibrosis. However, it is unknown if it has the same benefits in other hypersecretory pathologies.
Introduction: Nebulized hypertonic saline (HS) improves quality of life and reduces exacerbations in patients with cystic fibrosis. It is unknown if it would offer the same benefits in other hypersecretory pathologies.Methods: Retrospective observational study. Patients who passed the tolerance test and started HS 5.8% with one year of follow-up were included. Clinical and healthcare parameters were quantified in the year before and after the start of treatment.Results: 101 patients, 60.4% women, 65 years (95% CI: 62.4-67.9): 82 (81.2%) bronchiectasis, 6 (5.9%) COPD, 2 (2%) asthma, 1 (1%) ILD, and 10 (9.9%) other causes. There was a reduction in bronchorrhea (91.1% vs 75.2%), recurrent infections (57.4% vs 22.8%) and cycles of antibiotic therapy (1.54 vs 0.55), as well as an increase in FEV1 (1881 ml vs. 1942 ml) and a decrease in visits to primary care (2.94 vs. 1.1), emergencies (0.36 vs. 0.17) and hospitalizations (0.17 vs. 0.17). 06). 73 patients (72.3%) presented an adequate tolerance. Conclusion: Nebulization of HS 5.8% in patients with bronchial hypersecretion is safe and has a remarkable clinical and healthcare impact.(c) 2022 Elsevier Espan tilde a, S.L.U. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据